◆ 会议时间：2022年12月1日至3日
◆ 会议地点：日本 福冈
◆ 会议简介：
2022年第63届日本肺癌学会(JLCS)年会将于2022年12月1日至3日在日本福冈举行。
日本肺癌学会(JLCS)成立于1960年，原名为“肺癌研究会”，1966年更名为日本肺癌学会。日本肺癌学会(JLCS)致力于促进肺癌及其相关领域的多样性研究，提高社会对疾病的认识和理解。JLCS现拥有7400余名成员。JLCS的活动宣包括：举办学术会议；出版刊物；促进肺癌的研究、调查与教育；与国内外相关学术团体密切联系、合作与协调等等。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)
第63回日本肺癌学会学術集会
The 63rd Annual Meeting of the Japanese Lung Cancer Society
Date: 2022年12月1日 ～ 2022年12月3日
Venue: Fukuoka International Congress Center/福岡国際会議場; Marine Messe Fukuoka (Japan)
Theme: Conquer Lung Cancer – Bridge to the Future
摘要征集-Call for Papers
Submission Period： April 6th, 2022 ～May 25th, 2022
点此提交摘要>>>Submit Abstract>>>
Submission Guidelines
- Abstracts should be submitted in English.
- The abstract title should not exceed 100 characters and the text should not exceed 1,600 characters.
- If the content includes graphs or tables, the character count must not exceed 1,072 characters.
Greeting
The 63rd Annual Meeting of the Japanese Lung Cancer Society (JLCS2022 hereafter) will take place on December 1–3, 2022 at Fukuoka International Congress Center and Marine Messe Fukuoka. As the president, it is my great honor to host JLCS2022, the meeting focused on a specific type of cancer with the longest history and rich tradition through which the latest advances in lung cancer research and treatments have been discussed and developed. I would like to thank all the members of the Society. Initially, the host location Oita, the most famous hot springs spot in Japan was considered but we chose Fukuoka for all practical reasons including venue capacity, access and hospitality. The current plan is to welcome you in person at the conference venue along with hybrid operation.
The theme of the meeting is “Conquer Lung Cancer – Bridge to the Future”. Lung cancer researches and treatments by pioneers in the 20th century made significant progress thus greatly advanced to further progress in the 21st century with the help of new technology. Medical diagnosis and treatments are transforming at an accelerating pace today including molecular-targeted therapy and genomic medicine by elucidated pathologies, cancer immunotherapy, advanced imaging and the deployment of robotic and artificial intelligence technologies. We hope to connect these advances to the future until we achieve “Conquering Lung Cancer,” the never-dying ambition of all involved in lung cancer research and treatments. We are planning special lecture relays at which key experts and opinion leaders and the next generation specialist present in sequence to exhibit the sub-theme “Bridge to the Future”. We are also inviting renowned international experts to a variety of international sessions (likely to be held online).
The environment of medicine has changed considerably due to the COVID-19 pandemic since January 2020. Tirelessly new technology and supply of vaccines are being pursued to eradicate the pandemic, though the situation remains unpredictable with emerging variants. Optimistically I hope we gather together in December 2022 in person and engage in fruitful discussions. To this end, with the dedicated team members, I will do the best to prepare for a successful and safe conference.
I sincerely look forward to welcoming you in Fukuoka.
Kenji Sugio
Congress President of the 63rd Annual Meeting of the Japanese Lung Cancer Society
（Dean, Oita University Faculty of Medicine Professor, Department of Thoracic and Breast Surgery)
◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|
